Valeant says on hunt for more deals, including contact lenses

Thu Jul 31, 2014 10:27am EDT

The head offices of Valeant Pharmaceuticals International Inc. are seen in Laval, Quebec May 20, 2014.  REUTERS/Christinne Muschi

The head offices of Valeant Pharmaceuticals International Inc. are seen in Laval, Quebec May 20, 2014.

Credit: Reuters/Christinne Muschi

Related Topics

(Reuters) - Valeant Pharmaceuticals International Inc (VRX.TO) on Thursday said it remains on the hunt for other companies, including makers of innovative contact lenses, as it presses on with efforts to take over Botox-maker Allergan Inc (AGN.N).

On a conference call with investors, Valeant Chief Executive Officer Michael Pearson said the company will not be content to remain the No. 4 global player in the contact lens industry.

Valeant officials said Allergan shareholders would profit more through a merger with Toronto-based Valeant than remaining a standalone company.

The company said Allergan shareholders would receive about twice as much cash earnings per share - meaning profits adjusted for one-time items - in 2016 with a merged company, than if Allergan were to remain independent.

(Reporting by Ransdell Pierson; Editing by Jeffrey Benkoe)

FILED UNDER:
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (1)
songster wrote:
I can not wear contact lenses because I have a special refractive error. Because of this, unfortunately when will come the new google- lens with camera, I do not use it then.

Jul 31, 2014 12:23pm EDT  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.